MOTS-c 10 mg

MOTS-c 10 mg contains the mitochondrial-derived peptide MOTS-c. In research settings, MOTS-c has been studied for its roles in metabolic regulation, insulin sensitivity, and cellular stress responses. In non-medical bodybuilding contexts, MOTS-c is commonly referenced for its exercise-mimetic properties and support for metabolic conditioning, though such use is not supported by completed human clinical trials and falls outside approved indications.

There is no established human dosing schedule for MOTS-c. In non-medical research discussions, user-reported protocols typically reference 1 mg daily or 5 mg two to three times weekly. Some users follow a conservative titration starting at lower doses. These figures represent community-reported practices and are not derived from controlled clinical trials.

MOTS-c is a peptide and does not suppress endogenous testosterone production in the way anabolic steroids do. Post-cycle therapy is not applicable to MOTS-c in the context of hormonal recovery. Research protocols typically include an off-cycle period of 4–8 weeks following an 8–12 week active phase.

MOTS-c is a mitochondrial-derived peptide that functions as a retrograde signaling molecule. Its primary mechanism involves activation of AMPK, a cellular energy sensor that coordinates metabolic responses. Research has explored MOTS-c's roles in insulin sensitivity, metabolic homeostasis, and cellular stress resistance in preclinical models.

No established timeline exists for MOTS-c effects in humans. The ongoing Phase 2a trial evaluates 12 weeks of treatment, suggesting that meaningful metabolic effects may require sustained administration. In community-reported experiences, some users describe noticing energy or performance changes within the first few weeks, though these reports are anecdotal.

There is no universally established "best" metabolic peptide. Different peptides have distinct mechanisms and research applications. MOTS-c's primary focus is AMPK pathway activation and mitochondrial signaling, while other compounds may target different metabolic pathways. The appropriate choice depends on the specific research context and goals.

MOTS-c and Ipamorelin have fundamentally different mechanisms. MOTS-c is a mitochondrial-derived peptide that activates AMPK and regulates metabolic pathways. Ipamorelin is a growth hormone secretagogue that stimulates GH release. In non-medical research contexts, the two are sometimes discussed together for body recomposition, with MOTS-c addressing metabolic and fat-burning aspects while Ipamorelin supports GH-mediated recovery and muscle growth.

MOTS-c and TB 500 are distinct research peptides with different origins and mechanisms. MOTS-c is a mitochondrial-derived peptide involved in metabolic regulation, while TB 500 contains a thymosin beta 4 fragment with actin-binding properties. They are investigated in different research contexts and are not interchangeable.

Without established human dosing, no milligram amount can be classified as appropriate or excessive. MOTS-c 10 mg is labeled at 10 mg of lyophilized powder per vial. In non-medical research discussions, 10 mg represents a common single-vial size that may cover one to two weeks of a performance-oriented protocol, but this does not establish any dosing guidance.

MOTS-c 10 mg is labeled at 10 mg of MOTS-c peptide per vial. It is supplied as a lyophilized powder in a 2 mL vial manufactured by Axiolabs.

Yes. MOTS-c is prohibited by the World Anti-Doping Agency (WADA) under category S4 as an AMPK activator (metabolic modulator). Its use by athletes subject to anti-doping testing would constitute a doping violation. The ban applies at all times, both in-competition and out-of-competition.